A new cancer treatment administered through a simple injection has generated excitement among researchers after demonstrating the ability to completely eliminate tumors in some patients. The innovative therapy, known as amivantamab, produced encouraging outcomes in individuals with advanced cancers that had stopped responding to conventional treatments such as chemotherapy and immunotherapy.
The findings, presented at a major international oncology conference, suggest that this next-generation cancer therapy could offer new hope for patients with limited treatment options and improve outcomes for thousands of people diagnosed with aggressive cancers each year.
The international clinical trial involved 102 patients diagnosed with advanced head and neck cancer. All participants had experienced cancer progression or recurrence after standard treatment approaches had failed.
Researchers reported that the injection achieved positive responses in more than 40% of participants. Among those patients:
Cancer specialists described the results as highly encouraging, particularly because the trial focused on patients with treatment-resistant disease, a group that typically faces poor outcomes and limited therapeutic choices.
Unlike traditional cancer therapies that target a single pathway, amivantamab attacks cancer through three different mechanisms.
The drug inhibits EGFR, or epidermal growth factor receptor, a protein that plays a major role in helping cancer cells grow and multiply. Excessive EGFR activity is commonly associated with several types of cancer.
Cancer cells often develop resistance to treatment by activating alternative pathways. One of the most common escape routes is the MET signaling pathway. Amivantamab blocks this pathway, making it harder for cancer cells to survive and spread.
The treatment also helps stimulate the body's immune defenses, encouraging immune cells to recognize and attack cancerous tissue more effectively.
This combination approach may explain why the therapy achieved meaningful responses in patients whose cancers had already become resistant to multiple forms of treatment.
One of the most attractive features of amivantamab is its method of delivery.
Many cancer drugs require lengthy intravenous infusions in hospital settings. In contrast, amivantamab is administered as a small injection beneath the skin once every three weeks.
This offers several potential benefits:
Healthcare providers believe this simplified delivery method could improve patient experience while making treatment more accessible.
One patient who participated in the clinical trial was 56-year-old Carl Walsh, who was diagnosed with tongue cancer in 2024.
After undergoing chemotherapy and immunotherapy without success, he joined the OrigAMI-4 clinical trial in 2025. According to reports, the treatment significantly improved his condition.
Before receiving the injection, Walsh struggled with speaking and eating due to pain and swelling caused by his cancer. His diet was restricted to soft foods and nutritional supplements, and he experienced considerable weight loss.
However, after beginning treatment, his symptoms improved dramatically. The swelling decreased, pain levels reduced, and his ability to eat returned gradually. Within months, he was able to resume a normal diet and return to daily activities with far fewer limitations.
His experience highlights the potential quality-of-life improvements that effective cancer therapies can provide beyond simply extending survival.
Although the current study focused on head and neck cancer, researchers have reported promising activity in other cancer types as well.
Amivantamab is currently being investigated in approximately 60 clinical trials worldwide, including studies involving:
Scientists are hopeful that the therapy's unique mechanism of action may benefit a broader range of cancer patients in the future.
The trial also demonstrated encouraging survival results.
Patients treated with amivantamab achieved a median overall survival of approximately 12.5 months after beginning therapy. Considering that these individuals had advanced cancers that were no longer responding to standard treatments, researchers view this outcome as a meaningful improvement.
While further studies are necessary to confirm long-term benefits, the results suggest that the treatment may help patients live longer while maintaining a better quality of life.
Head and neck cancer remains one of the most common cancers globally and can be particularly challenging to treat when it recurs after standard therapy.
Researchers noted that the study specifically focused on patients whose cancers were not linked to human papillomavirus (HPV). These cancers are often more aggressive and historically have fewer successful treatment options.
Achieving substantial tumor responses in this patient population represents an important advancement in cancer research and may pave the way for new treatment strategies in difficult-to-treat cancers.
Although the findings are highly promising, amivantamab is still undergoing evaluation in ongoing clinical trials. Regulatory review and additional studies will be required before the treatment becomes widely available for all eligible cancer patients.
Future research will focus on:
Medical experts remain optimistic that these results could mark the beginning of a new era in targeted cancer treatment.
The emergence of amivantamab represents a potentially significant breakthrough in oncology. By simultaneously targeting cancer growth mechanisms and supporting the immune system, the treatment has demonstrated the ability to shrink or completely eliminate tumors in patients who had exhausted conventional treatment options.
While additional research is still needed, the early results provide genuine optimism for patients facing advanced cancers. If future trials continue to confirm these findings, amivantamab could become an important addition to the growing arsenal of precision cancer therapies designed to improve survival and quality of life.
This article is intended for informational and educational purposes only. It should not be considered medical advice, diagnosis, or treatment guidance. Patients should consult qualified healthcare professionals regarding any medical condition, treatment decisions, or participation in clinical trials. Clinical trial results are preliminary until fully reviewed by regulatory authorities and published in peer-reviewed medical journals.
The Guardian regarding clinical trial results presented at the 2026 annual meeting of the American Society of Clinical Oncology (ASCO), featuring research conducted by investigators from the Institute of Cancer Research (ICR), the Royal Marsden NHS Foundation Trust, and collaborating international research centers.
Most Accurate Healthcare AI designed for everything from admin workflows to clinical decision support.